NGM831

NGM831 · NGM Biopharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NGM831, covering 2024-10-10 to 2024-10-10. Get the full timeline:

Most recent: Clinical Trial Update: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors [Phase 1]

See pricing